Association of Stromal Cell–Derived Factor-1-3′A Polymorphism to Higher Mobilization of Hematopoietic Stem Cells CD34+ in Tunisian Population
Autor: | M. Ben Nasr, T. Ben Othmen, Z. Reguaya, M. Maamar, Fethi Mellouli, J. Domenech, Saloua Ladeb, L. Berraies, F. Jenhani, Mohamed Bejaoui |
---|---|
Rok vydání: | 2011 |
Předmět: |
Tunisia
Allogeneic transplantation CD34 Antigens CD34 Polymerase Chain Reaction hemic and lymphatic diseases Genotype Odds Ratio medicine Humans Transplantation Homologous Autologous transplantation Stromal cell-derived factor 1 Alleles Multiple myeloma Transplantation Polymorphism Genetic biology business.industry Lymphoma Non-Hodgkin medicine.disease Hodgkin Disease Chemokine CXCL12 Hematopoietic Stem Cell Mobilization Lymphoma Leukemia Myeloid Acute Immunology biology.protein Surgery Multiple Myeloma business Polymorphism Restriction Fragment Length |
Zdroj: | Transplantation Proceedings. 43:635-638 |
ISSN: | 0041-1345 |
DOI: | 10.1016/j.transproceed.2011.01.016 |
Popis: | We explored the influence of polymorphisms in genes encoding the chemokine stromal cell–derived factor-1 (SDF-1)/CXCL12 in a cohort of Tunisian patients with malignant hematologic diseases multiple myeloma [MM], non-Hodgkin's lymphoma [NHL], Hodgkin's disease, and acute myeloid leukemia [AML], who underwent stem cell mobilization for autologous transplantation versus a group of healthy donors for allogeneic transplantation. Polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLp) analysis was used for rapid identification of genotypes. Significant associations for SDF1-3′A polymorphism were observed exclusively in patients with MM and NHL. While there was a lack of all association of SDF-1 polymorphism with AML patients. However, considering that the ability of mobilization varies among subjects, we have observed that the SDF1-3′A allele was associated with good mobilization capacity. Interestingly, the association was mainly observed among healthy allogeneic transplant donors where the analysis was not biased by background disease or chemotherapy (P = .010; odds ratio = 2.603; confidence interval [95%] = 1.239–5.466). |
Databáze: | OpenAIRE |
Externí odkaz: |